Randomized adaptive assessment of post COVID syndrome treatments (RAPID): Evaluating the Efficacy of Bupropion for the Treatment of Post-COVID-19 Syndrome-associated Fatigue (ELAPSE)
This research study, called RAPID, is exploring new ways to treat people who are still struggling with symptoms after having COVID-19, often called Post-COVID Syndrome. Specifically, it focuses on helping with persistent tiredness (fatigue) and physical problems. The study will test a medication called Bupropion against a placebo, which is an inactive dummy pill. Researchers will carefully check how participants' tiredness levels change over time and how well they can do physical activities. The aim is to see if Bupropion can make a real difference to people's quality of life and help them recover more fully from the long-term effects of COVID-19.
At a glance
What is this study about?
This research study is called RAPID, which stands for "Randomized Adaptive Assessment of Post COVID Syndrome Treatments." It's specifically looking into problems that some people experience long after they've recovered from the initial COVID-19 infection, a condition often referred to as Post-COVID Syndrome. Many people in the UK have shared stories of continuing to feel extremely tired (fatigue) and having trouble with everyday physical activities months after their COVID-19 illness. This study aims to find effective treatments for these challenging symptoms.
The main goal of this particular part of the RAPID study, which is called ELAPSE, is to see if a medication called Bupropion can help reduce tiredness and improve physical function in people with Post-COVID Syndrome. Bupropion is a medicine that is sometimes used for other conditions, and researchers want to find out if it can also be helpful for those struggling with long-term COVID symptoms.
To ensure fair results, the study will compare Bupropion with a placebo. A placebo is a dummy pill that looks exactly like the real medicine but contains no active ingredients. This helps researchers understand if any improvements are genuinely due to the Bupropion or if they might happen naturally or due to the act of taking a pill. By doing this carefully, the study hopes to provide clear answers about whether Bupropion is a safe and effective treatment option.
Key takeaways
- This study investigates new treatments for long-term tiredness and physical issues after COVID-19.
- It compares the drug Bupropion with a dummy pill (placebo).
- Participation involves taking a capsule daily and attending regular clinic visits.
- The study aims to improve understanding and treatment of Post-COVID Syndrome.
- Your involvement could help many others facing similar challenges in the future.
- You can stop participating at any time if you change your mind.
Who may be eligible?
To be considered for this study, you need to be an adult, aged 18 years or older. There is no upper age limit, meaning people of all adult ages can potentially take part. Both men and women are welcome to participate in this research.
The study is specifically for people who have been diagnosed with Post-COVID Syndrome, meaning they are experiencing symptoms long after their initial COVID-19 infection.
There will be other specific health requirements and checks to make sure the study is right and safe for you. These will be discussed in detail by the study team, but generally involve your current health status and any other medications you might be taking.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with Post-COVID Syndrome (long COVID)?
- Are you able to attend appointments at the study clinic?
- Are you willing to take a study medication, which could be Bupropion or a placebo?
- Are you comfortable completing questionnaires about your health and feelings?
What does participation involve?
If you decide to take part in this study, you might receive either the study drug, Bupropion, or a dummy pill (placebo). You won't know which one you are getting, and neither will your study doctor, to ensure fairness in the results. Both the active drug and the placebo will come in a capsule form. Over the course of the study, you'll have several visits to the clinic for assessments. These visits will involve answering questions about your tiredness and how well you can do physical activities, and you'll likely complete questionnaires about your mood and other symptoms. The study also includes checks on your breathing and your ability to do a simple physical exercise test.
The main treatment period for the study drug will last for 56 days (about 8 weeks). After this, the researchers will continue to monitor your progress for another 28 days to see if any effects of the treatment last. In total, your participation in the study from the very beginning (screening) to the final check-up will last about 84 days, which is roughly 12 weeks.
Potential risks and benefits
Locations (1)
- —UnverifiedGermany
Common questions
What is Post-COVID Syndrome?
It's when you have ongoing symptoms, like tiredness and breathing problems, for weeks or months after having COVID-19.
What is Bupropion?
It's a medication that researchers are testing to see if it can help with tiredness and physical difficulties after COVID-19.
What is a placebo?
It's a dummy pill that looks like the real medicine but has no active ingredients. It helps check if the drug truly works.
How long will I be in the study?
The study will last for about 12 weeks in total, including treatment and follow-up periods.
Who can join this study?
Adults aged 18 and over, both men and women, who have Post-COVID Syndrome and meet other health requirements.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.